U.S. FDA approves TALVEY™ (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma
Last Updated: Tuesday, August 22, 2023
Accelerated approval of TALVEY™ (talquetamab-tgvs) was granted approval by the US FDA to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Advertisement
News & Literature Highlights